• Editorial|Open Access

    Targeted therapies in cancer: where are we going?

    Elisa Giovannetti, Jose A. Rodriguez
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:82-6. | doi:10.20517/cdr.2018.05
    Published on: 19 Jun 2018  | Viewed:1228  | Downloaded:90
    +HTML| PDF
  • Review|Open Access

    Drug targets and resistance mechanisms in multiple myeloma

    Janine Nass, Thomas Efferth
    Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood cancer (10%). A PubMed search has been conducted for English research papers and reviews published until January 2018. Numerous drugs are used in treatment of MM. These include the antineoplastic alkylating... Read more
    Cancer Drug Resist 2018;1:87-117. | doi:10.20517/cdr.2018.04
    Published on: 19 Jun 2018  | Viewed:2350  | Downloaded:147
    +HTML| PDF
Cancer Drug Resistance ISSN 2578-532X (Online)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.